Halozyme Therapeutics in (halo 1 08/15/28)
13F holders, Q3 2024 (September 30)9holders −1
3new positions
3sold out
$1.21avg. 13F price*
At the end of Q3 2024, 9 institutions reported holding Halozyme Therapeutics in (halo 1 08/15/28) in their 13F filings, down 1 from Q2 2024. 3 opened new positions and 3 sold out. The largest holders were Absolute Investment Advisers, LLC ($13.1M), Angelo Gordon & Co., L.P. ($4.5M) and Sonora Investment Management Group, LLC ($2.7M).
- Company
- Halozyme Therapeutics in (halo 1 08/15/28)
- CUSIP
- 40637HAF6
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $4.8M |
| Exits | 3 | $4.4M |
All 13F filers, Q2 2024 → Q3 2024: 3,761,419 shares bought and 4,197,000 shares sold, net −435,581 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Absolute Investment Advisers, LLC | 1.79% | No change | 11,000,000 | $13.1M |
| Angelo Gordon & Co., L.P. | 1.51% | New | 3,750,000 | $4.5M |
| Sonora Investment Management Group, LLC | 0.20% | Reduce -2.4% | 2,280,000 | $2.7M |
| Bank of New York Mellon Corp | 0.00% | Reduce -33.3% | 400,000 | $477K |
| Sei Investments Co. | 0.00% | No change | 322,000 | $382K |
| Nomura Holdings Inc. | 0.00% | New | 6,419 | $367K |
| Oppenheimer Asset Management Inc. | 0.00% | Reduce -5.4% | 176,000 | $209K |
| Stephens Inc. | 0.00% | Reduce -6.9% | 95,000 | $113K |
| Comerica Bank | 0.00% | New | 5,000 | $6K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 1 08/15/28)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 1 08/15/28) the manager owns.